nach oben

Current Rheumatology Reports

Erschienen in:

29.01.2021 | COVID-19 | Systemic Lupus Erythematosus (G Tsokos, Section Editor) Zur Zeit gratis

SARS-CoV-2 and Systemic Lupus Erythematosus

verfasst von: Aikaterini Thanou, Amr H. Sawalha

Erschienen in: Current Rheumatology Reports | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To summarize current knowledge of the impact of coronavirus disease 19 (COVID-19) on patients with systemic lupus erythematosus (SLE).

Recent Findings

Several observational studies, including case series, patient surveys, and patient registries, have examined the incidence and severity of COVID-19 in patients with SLE. Due to methodologic limitations (focus on sicker patients, exclusion of asymptomatic or mild cases, limited or inaccurate viral testing), it is difficult to determine the risk and outcomes of COVID-19 in SLE patients. Corticosteroids might be associated with increased hospitalizations from COVID-19 in individuals with autoimmune rheumatic diseases. Some immune suppressive treatments do not appear to significantly increase the risk of contracting COVID-19 or poor subsequent outcomes; however, data on the safety of specific drugs remain scarce. Studies in non-autoimmune cohorts have shown more severe COVID-19 in ethnic and racial minorities, populations also more heavily impacted by SLE. Such results have been attributed to highly prevalent socioeconomic disparities and comorbidities. The complex interplay between SARS-CoV-2 and the host immunologic milieu may have particular implications for patients with SLE that remain to be explored. Concerns have been raised of COVID-19 heightening the risk of thromboembolic events in the presence of an SLE-induced procoagulant state.

Summary

Limitations in epidemiologic data available to date do not allow for assessing the risk and severity of COVID-19 in patients with SLE. Other than corticosteroids, prior use of some immune suppressive medications does not appear to increase the risk for infection with SARS-CoV-2 however, more comprehensive studies are needed.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Na Rev Dis Primers. 2016;2:16039. https://doi.org/10.1038/nrdp.2016.39.CrossRef

Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448. https://doi.org/10.1016/j.clim.2020.108448.CrossRefPubMedPubMedCentral

Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286–94. https://doi.org/10.1177/0961203313493032.CrossRefPubMed

Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. https://doi.org/10.1136/bmj.m1966.CrossRefPubMedPubMedCentral

Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://doi.org/10.1136/bmj.m1985.CrossRefPubMedPubMedCentral

Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910–41. https://doi.org/10.1016/j.immuni.2020.05.002.CrossRefPubMedPubMedCentral

Sturrock BR, Milne KM, Chevassut TJ. The renin-angiotensin system - a therapeutic target in COVID-19? Clin Med (Lond). 2020;20(4):e72–e5. https://doi.org/10.7861/clinmed.2020-0146.CrossRef

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. https://doi.org/10.1111/joim.13091.CrossRefPubMed

• Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. https://doi.org/10.1016/j.autrev.2020.102567Comprehensive review of COVID-19 immunopathology.CrossRefPubMedPubMedCentral

10.

Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020;43:102174. https://doi.org/10.1016/j.msard.2020.102174.CrossRefPubMedPubMedCentral

11.

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheum. 2020;72(7):1059–63. https://doi.org/10.1002/art.41285.CrossRef

12.

Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, et al. SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis. Am J Clin Pathol. 2020;154(4):466–74. https://doi.org/10.1093/ajcp/aqaa124.CrossRefPubMed

13.

Zhang F, Mears JR, Shakib L, Beynor JI, Shanaj S, Korsunsky I, et al. IFN- gamma and TNF- alpha drive a CXCL10 + CCL2 + macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation. bioRxiv. 2020. https://doi.org/10.1101/2020.08.05.238360.

14.

Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11). https://doi.org/10.1172/jci.insight.138999.

15.

Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15. https://doi.org/10.1016/j.thromres.2020.06.029.CrossRefPubMedPubMedCentral

16.

Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. A reality check on antiphospholipid antibodies in COVID-19-associated coagulopathy. Arthritis Rheum. 2020. https://doi.org/10.1002/art.41472.

17.

Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16:581–9. https://doi.org/10.1038/s41584-020-0474-5.CrossRefPubMedPubMedCentral

18.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020;383(3):288–90. https://doi.org/10.1056/NEJMc2013656.CrossRefPubMed

19.

Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020;18:2191–201. https://doi.org/10.1111/jth.14994.CrossRefPubMed

20.

Mantovani Cardoso E, Hundal J, Feterman D, Magaldi J. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020. https://doi.org/10.1007/s10067-020-05310-1.

21.

Sawalha AH, Manzi S. Coronavirus Disease-2019: implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol. 2020;7:S117–20. https://doi.org/10.5152/eurjrheum.2020.20055.CrossRefPubMedPubMedCentral

22.

Sawalha AH. Patients with lupus are not protected from COVID-19. Ann Rheum Dis. 2020:annrheumdis-2020-217656. https://doi.org/10.1136/annrheumdis-2020-217656.

23.

Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. 2020;215:108410. https://doi.org/10.1016/j.clim.2020.108410.CrossRefPubMedPubMedCentral

24.

Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, et al. The CD38/NAD/SIRTUIN1/EZH2 Axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep. 2020;30(1):112–23 e4. https://doi.org/10.1016/j.celrep.2019.12.014.CrossRefPubMedPubMedCentral

25.

Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interf Cytokine Res. 2011;31(12):887–92. https://doi.org/10.1089/jir.2011.0071.CrossRef

26.

James JA, Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol. 2012;24(4):383–8. https://doi.org/10.1097/BOR.0b013e3283535801.CrossRefPubMedPubMedCentral

27.

Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20. https://doi.org/10.1016/j.jaut.2016.10.004.CrossRefPubMed

28.

Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis. 2020;79:1382–3. https://doi.org/10.1136/annrheumdis-2020-217717.CrossRefPubMed

29.

Favalli EG, Gerosa M, Murgo A, Caporali R. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis. 2020:annrheumdis-2020-217787. https://doi.org/10.1136/annrheumdis-2020-217787.

30.

Gendebien Z, von Frenckell C, Ribbens C, Andre B, Thys M, Gangolf M, et al. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments. Ann Rheum Dis. 2020:annrheumdis-2020-218244. https://doi.org/10.1136/annrheumdis-2020-218244.

31.

Goyal M, Patil P, Pathak H, Santhanam S, Goel A, Sharma V, et al. Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India. Ann Rheum Dis. 2020:annrheumdis-2020-218013. https://doi.org/10.1136/annrheumdis-2020-218013.

32.

Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837–9. https://doi.org/10.1136/annrheumdis-2020-217566.CrossRefPubMed

33.

Wallace B, Washer L, Marder W, Kahlenberg JM. Patients with lupus with COVID-19: University of Michigan experience. Ann Rheum Dis. 2020:annrheumdis-2020-217794. https://doi.org/10.1136/annrheumdis-2020-217794.

34.

Gartshteyn Y, Askanase AD, Schmidt NM, Bernstein EJ, Khalili L, Drolet R, et al. COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol. 2020;2(8):e452–e4. https://doi.org/10.1016/s2665-9913(20)30161-2.CrossRefPubMedPubMedCentral

35.

• Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41450Prospective cohort study of systematically collected patients with SLE and confirmed or suspected COVID-19 from New York City.

36.

• Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–66. https://doi.org/10.1136/annrheumdis-2020-217871Compreheinsive report of 600 patients with AIRDs and confirmed or suspected COVID-19 from the Global Rheumatology Alliance Registry.CrossRefPubMed

37.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–8. https://doi.org/10.1136/annrheumdis-2020-217424.CrossRefPubMed

38.

Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. 2020;47(8):1296. https://doi.org/10.3899/jrheum.200507.CrossRefPubMed

39.

Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. https://doi.org/10.1016/j.jaut.2020.102502.

40.

Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheum. 2020;72:1600–6. https://doi.org/10.1002/art.41388.CrossRef

41.

Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020;79(7):986–8. https://doi.org/10.1136/annrheumdis-2020-217903.CrossRefPubMed

42.

Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rua-Figueroa I, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988–90. https://doi.org/10.1136/annrheumdis-2020-217948.CrossRefPubMed

43.

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:1393–9. https://doi.org/10.1136/annrheumdis-2020-217984.CrossRefPubMed

44.

Marques C, Pinheiro MM, Reis Neto ET, Dantas AT, Ribeiro FM, Melo AKG. COVID-19 in patients with rheumatic diseases: what is the real mortality risk? Ann Rheum Dis. 2020:annrheumdis-2020-218388. https://doi.org/10.1136/annrheumdis-2020-218388.

45.

Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and DMARDs on clinical outcomes. Arthritis Rheum. 2020;72:1981–9. https://doi.org/10.1002/art.41456.CrossRef

46.

Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020;383(1):85–8. https://doi.org/10.1056/NEJMc2009567.CrossRefPubMed

47.

• D'Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217888Cohort study of patients with AIRD and COVID-19 matched to non-AIRD comparators from a large heathcare system in the greater Boston area.

48.

Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323:2466–7. https://doi.org/10.1001/jama.2020.8598.CrossRefPubMed

49.

Feldman CH, Ramsey-Goldman R. Widening disparities among patients with rheumatic diseases in the COVID-19 era: an urgent call to action. Arthritis Rheum. 2020;72:1409–11. https://doi.org/10.1002/art.41306.CrossRef

50.

Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013;65(3):753–63. https://doi.org/10.1002/art.37795.CrossRefPubMedPubMedCentral

51.

Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception cohort. Ann Rheum Dis. 2015;74(9):1706–13. https://doi.org/10.1136/annrheumdis-2013-205171.CrossRefPubMed

52.

Gómez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcón GS, Costenbader KH. Racial/ethnic variation in all-cause mortality among United States Medicaid recipients with systemic lupus erythematosus: a Hispanic and Asian paradox. Arthritis Rheum. 2015;67(3):752–60. https://doi.org/10.1002/art.38981.CrossRef

53.

Lai Q, Spoletini G, Bianco G, Graceffa D, Agnes S, Rossi M, et al. SARS-CoV2 and immunosuppression: a double-edged sword. Transpl Infect Dis. 2020:e13404. https://doi.org/10.1111/tid.13404.

54.

Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40(8):843–56. https://doi.org/10.1002/phar.2438.CrossRefPubMed

55.

Scheetz MH, Konig MF, Robinson PC, Sparks JA, Kim AHJ. A pharmacokinetics-informed approach to navigating hydroxychloroquine shortages in patients with rheumatic disease during the COVID-19 pandemic. ACR Open Rheumatol. 2020. https://doi.org/10.1002/acr2.11164.

56.

Mendel A, Bernatsky S, Askanase A, Bae SC, Clarke AE, Costedoat-Chalumeau N, et al. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Ann Rheum Dis. 2020:annrheumdis-2020-218164. https://doi.org/10.1136/annrheumdis-2020-218164.

57.

Ruiz-Irastorza G, Martín-Iglesias D, Soto-Peleteiro A. Update on antimalarials and systemic lupus erythematosus. Curr Opin Rheumatol. 2020;Publish Ahead of Print. https://doi.org/10.1097/bor.0000000000000743.

58.

Das RR, Jaiswal N, Dev N, Jaiswal N, Naik SS, Sankar J. Efficacy and safety of anti-malarial drugs (chloroquine and hydroxy-chloroquine) in treatment of COVID-19 infection: a systematic review and meta-analysis. Front Med. 2020;7:482. https://doi.org/10.3389/fmed.2020.00482.CrossRef

59.

Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Rev Anti-Infect Ther. 2020:1–12. https://doi.org/10.1080/14787210.2020.1799785.

60.

Konig MF, Gianfrancesco M, Yazdany J, Robinson PC. Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217990.

61.

Singer ME, Kaelber DC, Antonelli MJ. Hydroxychloroquin ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis. Ann Rheum Dis. 2020:annrheumdis-2020-218500. https://doi.org/10.1136/annrheumdis-2020-218500.

62.

Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;71(15):799–806. https://doi.org/10.1093/cid/ciaa351.CrossRefPubMed

63.

• Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41437Guidelines by the ACR on the management of patients with AIRDs during COVID-19.

64.

Chatterjee K, Wu CP, Bhardwaj A, Siuba M. Steroids in COVID-19: an overview. Cleve Clin J Med. 2020. https://doi.org/10.3949/ccjm.87a.ccc059.

65.

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.

66.

Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2020;20(7):1800–8. https://doi.org/10.1111/ajt.15941.CrossRef

67.

Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheum. 2019;71(7):1125–34. https://doi.org/10.1002/art.40861.CrossRef

68.

Montastruc F, Renoux C, Hudson M, Dell'Aniello S, Simon TA, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: a population-based cohort study. Semin Arthritis Rheum. 2019;48(6):1053–8. https://doi.org/10.1016/j.semarthrit.2019.01.009.CrossRefPubMed

69.

Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2020:annrheumdis-2020-217549. https://doi.org/10.1136/annrheumdis-2020-217549.

70.

Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum. 2020;50(4):680–6. https://doi.org/10.1016/j.semarthrit.2020.05.010.CrossRefPubMedPubMedCentral

71.

Fallet B, Kyburz D, Walker UA. Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment. Arthritis Rheum. 2020;72:1581–2. https://doi.org/10.1002/art.41380.CrossRef

72.

Tudesq JJ, Cartron G, Rivière S, Morquin D, Iordache L, Mahr A, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev. 2018;17(2):115–24. https://doi.org/10.1016/j.autrev.2017.11.015.CrossRefPubMed

73.

Kado R, Sanders G, McCune WJ. Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol. 2016;28(3):251–8. https://doi.org/10.1097/bor.0000000000000272.CrossRefPubMed

74.

Fung M, Babik JM. COVID-19 in Immunocompromised hosts: what we know so far. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa863.

75.

Landewe RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851–8. https://doi.org/10.1136/annrheumdis-2020-217877.CrossRefPubMed

Titel: SARS-CoV-2 and Systemic Lupus Erythematosus
verfasst von: Aikaterini Thanou
Amr H. Sawalha
Publikationsdatum: 29.01.2021
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Current Rheumatology Reports / Ausgabe 2/2021
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-020-00973-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

SARS-CoV-2 and Systemic Lupus Erythematosus